The United Arab Emirates has approved a new medicine for the treatment of heart disease to reduce the risk of death.
The Emirates Drug Establishment announced on Monday that it has approved a new medicine, Inpefa (sotagliflozin), for the treatment of heart failure.
With this approval, the UAE has become the second country in the world to authorize this therapy.
Inpefa (sotagliflozin) is the first dual SGLT1 and SGLT2 inhibitor approved for the treatment of heart failure.
It is an oral medicine that helps regulate blood glucose levels while supporting heart and kidney health.
The EDE said the treatment has been approved to reduce the risk of death from cardiovascular diseases, lower hospitalizations due to heart failure, and reduce urgent medical visits related to the condition in adults with heart failure, type 2 diabetes, chronic kidney disease, or other cardiovascular risk factors.
